ABSTRACT
A biopsy-proven patient with prostate carcinoma aged 70 years was referred to the department of nuclear medicine for radionuclide-based therapy. His prostate-specific antigen levels were >1000 ng/mL, and prostatic magnetic resonance imaging showed an enlarged prostate with a heterogeneous signal and size 3.8x3.7x3.5 cm with few small heterogeneous nodular signals in the transition zone. He was scheduled for 18F prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scan before therapy. 18F PSMA PET/CT revealed PSMA-expressing prostate lesions (maximum standardized uptake value ~10.2) with extension into the urinary bladder along with bilateral supraclavicular, mediastinal, retrocrural, retroperitoneal, and pelvic lymph nodes and sclerotic lesions in the entire axial and appendicular skeleton.
Keywords:
Superscan, prostate carcinoma, 18F PSMA PET/CT, 18F prostate-specific membrane antigen
References
1Liu Y. Super-superscan on a bone scintigraphy. Clin Nucl Med 2011;36:227-228.
2Buckley O, O’Keeffe S, Geoghegan T, Lyburn ID, Munk PL, Worsley D, Torreggiani WC. 99mTc bone scintigraphy superscans: a review. Nucl Med Commun 2007;28:521-527.
3Chan M, Schembri GP. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT “superscan” in metastatic pancreatic neuroendocrine tumor. Clin Nucl Med 2017;42:108-109.
4Chakraborty PS, Sharma P, Karunanithi S, Bal C, Kumar R. Metastatic superscan on (99m)Tc-MDP bone scintigraphy in a case of carcinoma colon: Common finding but rare etiology. Indian J Nucl Med 2014;29:158-159.
5Agarwal KK, Tripathi M, Kumar R, Bal C. Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan. Indian J Nucl Med 2016;31:150-151.
6Awenat S, Piccardo A, Carvoeiras P, Signore G, Giovanella L, Prior JO, Treglia G. Diagnostic role of 18F-PSMA-1007 PET/CT in prostate cancer staging: a systematic review. Diagnostics (Basel) 2021;11:552.
7Ferrari M, Treglia G. 18F-PSMA-1007 pET in biochemical recurrent prostate cancer: an updated meta-analysis. Contrast Media Mol Imaging 2021;2021:3502389.
8Wang Z, Zheng A, Li Y, Dong W, Liu X, Yuan W, Gao F, Duan X. 18F-PSMA-1007 PET/CT performance on risk stratification discrimination and distant metastases prediction in newly diagnosed prostate cancer. Front Oncol 2021;11:759053.
